Wilson Therapeutics appoints Rick Lilley as Chief Regulatory Officer
Wilson Therapeutics AB (publ), announces the appointment of Rick Lilley as Chief Regulatory Officer. Dr Lilley will report to CEO Jonas Hansson and will join the company’s management team.
Dr Lilley is a senior global regulatory executive with more than 30 years of experience in the pharmaceutical and biotech industries with a strong track record of achievements and leadership in regulatory affairs and drug development in Europe, Japan and USA. He has successfully led the regulatory process through registration and approval for more than 20 products, including orphan drugs, in diverse therapeutic areas.
Most recently Dr Lilley served as Senior Vice President and Head of Global Regulatory Affairs at Vertex Pharmaceuticals where he was responsible for the global filings for the breakthrough orphan drug Orkambi that was approved in the US and EU during 2015. Prior to Vertex, Dr Lilley was Vice President and Head of Global Regulatory Affairs at UCB. He has also held senior regulatory positions at Johnson & Johnson, Shire and AstraZeneca. Dr Lilley received his BSc in Microbiology and Genetics as well as his PhD in Molecular Genetics from Queen Mary College, University of London.
“I am very excited to join Wilson Therapeutics at such an important point in time,” said Rick Lilley. “My drive has always been to bring innovative medicines to market to improve the lives of patients and in my career I have been fortunate to succeed with this numerous times. I will now focus all my attention on the Decuprate® program to help bring this highly promising product candidate through late stage development and product registration.”
“I am very pleased to welcome Rick to our executive team,” said Jonas Hansson, CEO of Wilson Therapeutics. “Rick brings a wealth of global regulatory and development expertise and has a proven track record, having been responsible for the registration of multiple innovative drugs in the US, Europe and Japan. His knowledge and experience will be tremendously valuable for us as we move the Decuprate® program forward.”
About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, Decuprate®, is initially being developed as a novel treatment for Wilson Disease and is currently being evaluated in a Phase II clinical study. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.
Visit www.wilsontherapeutics.com for more information.
For further information contact:
Jonas Hansson, CEO, Wilson Therapeutics AB
Telephone: +46 8 796 00 00
Email: jonas.hansson@wilsontx.eu
Wilson Therapeutics AB (publ)
Org nr 556893-0357
Västra Trädgårdsgatan 15
SE-111 53 Stockholm
The information in the press release is such that Wilson Therapeutics is required to disclose publicly in accordance with the Swedish Securities Market Act. The information was submitted for publication on June 16, 2016 at 8:30 a.m.
Tags: